IL17A and psoriasis: Uluçkan et al. observed in psoriasis patients with no joint involvement and with increased serum IL-17A levels a significant decrease in bone parameters, such as trabecular bone mineral density (BMD) and bone volume, together with decreases in bone formation biomarkers, such as amino pro-peptide of type 1 collagen (P1NP) and osteocalcin.